Abstract
Assessing the impact of mobility on epidemic spreading is of crucial importance for understanding the effect of policies like mass quarantines and selective re-openings. High mobility between areas contribute to the importation of cases, affecting the spread of the disease. While many factors influence local incidence and making it more or less homogeneous with respect to other areas, the importance of multi-seeding has often been overlooked. Multi-seeding occurs when several independent (non-clustered) infected individuals arrive at a susceptible population. This can give rise to autonomous outbreaks that impact separate areas of the contact (social) network. Such mechanism has the potential to boost local incidence and size, making control and tracing measures less effective. In Spain, the high heterogeneity in incidence between similar areas despite the uniform mobility control measures taken suggests that multi-seeding could have played an important role in shaping the spreading of the disease. In this work, we focus on the spreading of SARS-CoV-2 among the 52 Spanish provinces, showing that local peaks of incidence and mortality strongly correlate with mobility occurred in the early-stage weeks from and to Madrid, the main mobility hub and where the initial local outbreak unfolded. These results clarify the higher order effects that mobility can have on the evolution of an epidemic and highlight the relevance of its control.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
M.M. is funded by the Conselleria d'Innovacio, Recerca i Turisme of the Government of the Balearic Islands and the European Social Fund with grant code FPI/2090/2018. M.M., S.M. and J.J.R. also acknowledge funding from the project Distancia-COVID (CSIC-COVID-19) of the CSIC funded by a contribution of AENA, from the Spanish Ministry of Science, Innovation and Universities, the AEI and FEDER (EU) under the grant PACSS (RTI2018-093732-B-C22) and the Maria de Maeztu program for Units of Excellence in R&D (MDM-2017-0711).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
The information on mobility are available upon request with the permission of Kido Dynamics SA. The data on incidence and mortality can be downloaded from [29] and the one on the antibody prevalence from https://www.mscbs.gob.es/gabinetePrensa/notaPrensa/pdf/13.05130520204528614.pdf.
